HONG KONG – China's proposed biosimilar guidelines could open the door for more competition among domestic and foreign producers even though some issues remain unclear, such as the development of more complex next-generation products and how regulators will deal with naming issues.
HONG KONG – After years of waiting, Chinese biosimilar makers will soon have a comprehensive set of guidelines to follow, likely tipping the scales to make the massive country one of the top markets for biosimilars.
HONG KONG – Samsung Bioepis Co. Ltd., the biopharmaceutical arm of the South Korean conglomerate, is looking to take high-quality biosimilars global in just two years. For the company, which is expanding its footprint in that competitive space, it all comes down to 2016.
HONG KONG – This year has been a good one for biopharma companies in China, many of which are combining a growing market with stronger R&D pipelines, some government support and more tightly controlled expenses and are turning out some positive results.
HONG KONG – This year has been a good one for biopharma companies in China, many of which are combining a growing market with stronger R&D pipelines, some government support and more tightly controlled expenses and are turning out some positive results.
HONG KONG – After years of waiting, Chinese biosimilar makers will soon have a comprehensive set of guidelines to follow, likely tipping the scales to make the massive country one of the top markets for biosimilars.
HONG KONG – Samsung Bioepis Co. Ltd., the biopharmaceutical arm of the South Korean conglomerate, is looking to take high-quality biosimilars global in just two years. For the company, which is expanding its footprint in that competitive space, it all comes down to 2016.
SEOUL, South Korea – South Korean companies focused on research and development of stem cell therapy products are working hard to put the country back into a position of global leadership, even after setbacks in the last decade that held back research for years.
SEOUL, South Korea – Vaccine makers in Asian emerging markets are stepping up their development efforts, while researchers are increasingly helping developing countries troubled by neglected diseases by partnering with domestic manufactures, often in neighboring countries.
SEOUL, South Korea – South Korean companies focused on research and development of stem cell therapy products are working hard to put the country back into a position of global leadership, even after setbacks in the last decade that held back research for years.
